Literature DB >> 9657401

Left ventricular ejection fraction in patients with normal and distorted left ventricular shape by three-dimensional echocardiographic methods: a comparison with radionuclide angiography.

Y F Nosir1, A Salustri, J D Kasprzak, C S Breburda, F J Ten Cate, J R Roelandt.   

Abstract

BACKGROUND: Serial evaluation of left ventricular (LV) ejection fraction (EF) is important for the management and follow-up of cardiac patients. Our aim was to compare LVEF calculated from two three-dimensional echocardiographic (3DE) methods with multigated radionuclide angiography (RNA), in patients with normal and abnormally shaped ventricles. METHODS AND
RESULTS: Forty-one consecutive patients referred for RNA underwent precordial rotational 3DE acquisition of 90 cut-planes. From the volumetric data set, LVEF was calculated by (a) Simpson's rule (3DS) through manual endocardial tracing of LV short-axis series at 3 mm slice distance and (b) apical biplane modified Simpson's method ( MS) in 29 patients by manual endocardial tracing of the apical four-chamber view and its computer-derived orthogonal view. Patients included three groups: A, 17 patients with LV segmental wall motion abnormalities; B, 13 patients with LV global hypokinesis; and C, 11 patients with normal LV wall motion. For all the 41 patients, there was excellent correlation, close limits of agreement, and nonsignificant difference between 3DS and RNA for LVEF calculation (r = 0.99, [-6.7, +6.9] and p = 0.9), respectively. For the 29 patients, excellent correlation and nonsignificant differences between LVEF calculated by both 3DS and BMS and values obtained by RNA were found (r = 0.99 and 0.97, p = 0.7 and p = 0.5, respectively). In addition, no significant difference existed between values of LVEF obtained from RNA, 3DS, and BMS by the analysis of variance (p = 0.6). The limits of agreement tended to be closer between 3DS and RNA (-6.8, +7.2) than between BMS and RNA (-8.3, +9.7). The intraobserver and inter-observer variability of RNA, 3DS, and BMS for calculating LVEF(%) were (0.8, 1.5), (1.3, 1.8), and (1.6, 2.6), respectively. There were closer limits of agreement between 3DS and RNA for LVEF calculation in A, B, and C patient subgroups [(-3.5, +5), (-8.4, +5.6), and (-7.8, +8.6)] than that between BMS and RNA [(-8.1, +10.7), (-11.9, +9.3), and (-9.1, +11.3)], respectively.
CONCLUSIONS: No significant difference existed between RNA, 3DS, and BMS for LVEF calculation. 3DS has better correlation and closer limits of agreement than BMS with RNA for LVEF calculation, particularly in patients with segmental wall motion abnormalities and global hypokinesis. 3DS has a comparable observer variability with RNA. Therefore the use of 3DS for serial accurate LVEF calculation in cardiac patients is recommended.

Entities:  

Mesh:

Year:  1998        PMID: 9657401     DOI: 10.1016/s0894-7317(98)70038-0

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  3 in total

1.  Potential of right to left ventricular volume ratio measured on chest CT for the prediction of pulmonary hypertension: correlation with pulmonary arterial systolic pressure estimated by echocardiography.

Authors:  Heon Lee; Seok Yeon Kim; Soo Jeong Lee; Jae Kyun Kim; Ryan P Reddy; U Joseph Schoepf
Journal:  Eur Radiol       Date:  2012-04-27       Impact factor: 5.315

2.  Volume measurements in nuclear medicine gated SPECT and 4D echocardiography: validation using a dynamic cardiac phantom.

Authors:  Dominique Debrun; Fabienne Thérain; Long-Dang Nguyen; Christophe P Léger; Jacco J N Visser; Ellinor Busemann-Sokole
Journal:  Int J Cardiovasc Imaging       Date:  2005 Apr-Jun       Impact factor: 2.357

Review 3.  LVEF by Multigated Acquisition Scan Compared to Other Imaging Modalities in Cardio-Oncology: a Systematic Review.

Authors:  Markella I Printezi; Laura I E Yousif; Janine A M Kamphuis; Linda W van Laake; Maarten J Cramer; Monique G G Hobbelink; Folkert W Asselbergs; Arco J Teske
Journal:  Curr Heart Fail Rep       Date:  2022-03-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.